Alemtuzumab Therapy for Leukemic Cutaneous T-Cell Lymphoma: Diffuse Erythema as a Positive Predictor of Complete Remission
Low-dose alemtuzumab (LDA) therapy is highly effective and generally well tolerated for refractory cutaneous T-cell lymphoma (CTCL) with peripheral blood disease.
1 Treatment with LDA is effective in patients with blood involvement (leukemic (shown in red) had a T CM phenotype. Clinically, diffuse erythema cleared in this patient after LDA therapy, but discrete lesions remained. C, In 2 patients, diffuse erythema cleared after LDA therapy, but localized skin lesions clinically worsened despite reduction of the malignant clone in the skin. In the graphs, the black dots represent nonclonal T cells; malignant T cells are shown in red. Skin biopsies demonstrated that the malignant clone had been reduced from 50% before LDA therapy to 9% afterwards. Worsening skin lesions were infiltrated by highly activated interferon-γ (IFNγ)-producing nonclonal CD8 + T cells, suggesting that inflammation was mediated by activation of benign reactive T cells. Histograms on the right are gated to show only CD8 + T cells.
Methods | Work was performed according to the ethical principles set out in the Declaration of Helsinki and was approved by the Dana-Farber Cancer Institute institutional review board. All patients provided written informed consent. T cells isolated from skin 3 or blood were stained with directly conjugated monoclonal antibodies and analyzed on a Becton-Dickinson FACSCanto using FACSDiva software (version 5.1).
Results | Diffuse Cutaneous Erythema Without Discrete Plaques and/or Tumors Associated With Complete Remission
After LDA Therapy. Twenty-three patients with peripheral blood disease (eTable 1 in the Supplement) were treated with LDA (10 mg subcutaneously, 3 times a week). Of these, 17 patients presented with diffuse erythema without superimposed plaques or tumors ( Figure 1A) . Thirteen patients experienced complete remission following LDA treatment, and the remaining 4 had residual or emergent skin disease controllable by skin-directed therapy alone (eTable 1 in the Supplement). In contrast, of 6 patients presenting with discrete patches, plaques, or tumors with or without background diffuse erythema ( Figure 1B) , none experienced full remission after LDA; 1 responded fully to subsequent electron beam therapy, and 5 had recurrent and/or progressive disease, including 2 patients who developed large cell transformation. . Of 10 patients with greater than 80% T CM , 8 experienced full remission with LDA alone (Figure 2A) , and 2 after subsequent skin-directed therapies (eTable 1 in the Supplement). Of 9 patients with less than 80% T CM , 3 cleared after LDA therapy alone, and 6 had persistent and/or progressive disease ( Figure 2B ). The proportion of malignant T CM in skin could be measured in 12 patients; in 4 of 6 patients with greater than 80% T CM in skin, disease cleared with LDA therapy alone; in 1 of 6 it cleared with LDA plus skin-directed therapy; and in 1 of 6, the disease progressed. Two patients with different clones in the blood and skin did not experience complete clearance with LDA therapy alone but experienced full remission after additional skin-based therapies (eTable 1 in the Supplement). In 2 patients with worsening skin disease during or after LDA therapy, biopsies showed large numbers of nonclonal, activated, interferon-γ-producing CD8 + T cells, suggesting that inflammation was mediated by benign T cells ( Figure 2C ).
Circulating Malignant T Cells With a T CM Phenotype Correlation
Discussion | All patients treated with LDA had clearance of peripheral blood disease, but only patients presenting with diffuse erythema without superimposed plaques or tumors also had complete and long-lasting clearance of skin disease. Initial clinical presentation was more predictive of response than was complex cellular phenotyping of T cells from blood and skin. In other words, the eyes of a well-trained dermatologist were more powerful than a comprehensive translational research program in identifying complete responders to LDA therapy. On a scientific level, diffuse erythema is likely caused by migrating T cells, and only T cells that migrate into blood are cleared by LDA. Fixed skin lesions are more likely to be caused by T RM , cells that escape LDA clearance by remaining long-term in skin. Based on our clinical and scientific findings, we recommend the use of LDA with or without adjuvant skin-directed therapy in patients with diffuse cutaneous erythema, but we caution against its use in patients with preexisting plaques and/or tumors.
